Monopar Therapeutics (MNPR) Enterprise Value Growth (1y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.96% |
| Sep 30, 2025 | -2,020.86% |
| Jun 30, 2025 | -545.46% |
| Mar 31, 2025 | -408.63% |
| Dec 31, 2024 | -530.55% |
| Sep 30, 2024 | -9.15% |
| Jun 30, 2024 | 15.17% |
| Mar 31, 2024 | -36.36% |
| Dec 31, 2023 | 11.24% |
| Sep 30, 2023 | 60.39% |
| Jun 30, 2023 | 56.18% |
| Mar 31, 2023 | 67.87% |
| Dec 31, 2022 | 59.10% |
| Sep 30, 2022 | 37.68% |
| Jun 30, 2022 | 30.95% |
| Mar 31, 2022 | 30.73% |
| Dec 31, 2021 | -19.58% |
| Sep 30, 2021 | -24.24% |
| Jun 30, 2021 | -90.04% |
| Mar 31, 2021 | -104.28% |
| Dec 31, 2020 | -26.66% |
| Sep 30, 2020 | -300.10% |
| Jun 30, 2020 | -144.57% |
| Mar 31, 2020 | -114.12% |
| Dec 31, 2019 | -91.71% |
| Sep 30, 2019 | 41.00% |
| Jun 30, 2019 | 37.58% |
| Mar 31, 2019 | 34.46% |
| Dec 31, 2018 | 23.26% |
| Sep 30, 2018 | 28.05% |
| Jun 30, 2018 | -91.96% |
| Mar 31, 2018 | -152.65% |
| Dec 31, 2017 | -212.63% |